Quick Answer
Xilio Therapeutics, Inc. reported Diluted EPS of $4.19 per share (loss) for fiscal year 2025.
Xilio Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$4.19 | +72.5% |
| 2024 | -$15.24 | -448.2% |
| 2023 | -$2.78 | +13.7% |
| 2022 | -$3.22 | +76.2% |
| 2021 | -$13.52 | +87.2% |
| 2020 | -$105.42 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.11 | +50.0% | +31.2% |
| June 30, 2025 | -$0.16 | +33.3% | +11.1% |
| March 31, 2025 | -$0.18 | +71.0% | +18.2% |
| September 30, 2024 | -$0.22 | +63.9% | +8.3% |
| June 30, 2024 | -$0.24 | +65.7% | +61.3% |
| March 31, 2024 | -$0.62 | +25.3% | -1.6% |
| September 30, 2023 | -$0.61 | +15.3% | +12.9% |
| June 30, 2023 | -$0.70 | +22.2% | +15.7% |
- Xilio Therapeutics, Inc. showed an increase of +72.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Xilio Therapeutics, Inc.’s diluted eps has grown by 96.0% (from $105.42 per share (loss) to $4.19 per share (loss)).
- The most recent figure is from Xilio Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: